info@flamel.com
Company | Technologies and Products | Investor Relations | Press Releases | Contact
 
Nicolas Flamel (1330-1418)
was a French alchemist
in the Middle Ages...
learn more

Flamel Technologies is a drug delivery company with expertise in polymer chemistry.

 
The company was founded in 1990.
 
In 1996, Flamel Technologies (FLML) became the second French biotech company to enter the Nasdaq.
 
The Company has assembled a strong team of researchers expert in polymer science and biochemistry, and owns cGMP pharmaceutical production facility of over 100,000 square feet located in Pessac, France.
 
Flamel’s drug delivery platforms, Medusa® for therapeutic proteins and peptides, and Micropump® for small molecules , have been developed to improve the therapeutic characteristics, safety profile and ease of use of wide variety of drugs.
 
The Company is a recognized world leader in the innovation of delivery systems for small molecule and protein drugs, providing tailored solutions to the biotech and pharmaceutical industries for optimized controlled-release delivery of drugs. Flamel is turning already-marketed or new drugs into more effective and safer medicines for itself and for its partners.
 
Flamel has partnership agreements with major pharmaceutical companies:

The Company is actively seeking partnership agreements for the development and commercialization of products currently in its pipeline as well as for new products using Flamel’s proprietary delivery systems.

Latest News

Flamel Technologies Corporate Presentation - January 2010
To view the latest presentation, click here.

December 18, 2009
Flamel Technologies Announces the Initiation of a Phase 2a Clinical Trial of Flamel's IFN-Alpha-2b XL in Patients with Chronic Hepatitis C Virus Infection

November 16, 2009
Flamel Technologies Announces Third Quarter 2009 Results; Additional New Projects; Cash Increases from $45.1 to $48.8 million
A conference call to discuss earnings is scheduled for 8:30 AM EST November 16, 2009.
The dial-in number (for investors in the U.S. and Canada) is 1-800-860-2442; the conference ID number is 435349.
International investors are invited to dial 1 412-858-4600.
 Webcast

November 04, 2009
Flamel Technologies Announces Licensing Agreement with Pfizer

 
Latest News Medusa ® Micropump ® Technologies

December 18, 2009
Flamel Technologies Announces the Initiation of a Phase 2a Clinical Trial of Flamel's IFN-Alpha-2b XL in Patients with Chronic Hepatitis C Virus Infection

November 16, 2009
Flamel Technologies Announces Third Quarter 2009 Results; Additional New Projects; Cash Increases from $45.1 to $48.8 million
A conference call to discuss earnings is scheduled for 8:30 AM EST November 16, 2009.
The dial-in number (for investors in the U.S. and Canada) is 1-800-860-2442; the conference ID number is 435349.
International investors are invited to dial 1 412-858-4600.
 Webcast

November 04, 2009
Flamel Technologies Announces Licensing Agreement with Pfizer

September 18, 2009
Flamel Technologies to Present at UBS Global Life Sciences Conference – 10 a.m. ET
Webcast

A Versatile Nano Carrier for the Delivery of Native Proteins

Medusa®, a self-assembled poly-aminoacid nanoparticles system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. more info

From Pediatric to Geriatric Uses

Controlled-release systems permitting either extended (Micropump® I) or both delayed and extended (Micropump® II) delivery of small molecule drugs.

more info
 
Micropump® and Medusa® are registered trademarks of Flamel Technologies S.A.
Copyrights © 2010 Flamel Technologies S.A. All rights reserved